Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yale, J. F.
Right arrow Articles by Posner, B. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yale, J. F.
Right arrow Articles by Posner, B. I.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 44, Issue 11 1274-1279, Copyright © 1995 by American Diabetes Association

ARTICLES

Hypoglycemic effects of peroxovanadium compounds in Sprague-Dawley and diabetic BB rats

JF Yale, D Lachance, AP Bevan, C Vigeant, A Shaver and BI Posner
McGill Nutrition and Food Science Centre, McGill University, Montreal, Quebec, Canada.

Highly purified peroxovanadium (pV) compounds, each containing an oxo ligand, one or two peroxo anions, and an ancillary ligand in the inner coordination sphere of vanadium, were shown to decrease plasma glucose markedly in both normal Sprague-Dawley and insulin-deprived diabetic BB rats. Maximal decreases in plasma glucose were at 60-100 min after intravenous, intraperitoneal, or subcutaneous administration. Synergism between these compounds and insulin was observed. Whereas parenterally administered orthovanadate or vanadyl sulfate did not induce hypoglycemia before inducing acute mortality, pV compounds effected hypoglycemia at doses much lower than those inducing acute mortality. When administered subcutaneously over a period of 3 days to insulin-deprived diabetic BB rats, pV compounds, but not vanadate, caused a significant decrease in plasma glucose concentrations and prevented the appearance of ketosis in these animals. Thus, pV compounds are the first agents other than insulin that acutely and markedly reduce plasma glucose in hypoinsulinemic diabetic BB rats.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
L. Marti, A. Abella, C. Carpene, M. Palacin, X. Testar, and A. Zorzano
Combined Treatment With Benzylamine and Low Dosages of Vanadate Enhances Glucose Tolerance and Reduces Hyperglycemia in Streptozotocin-Induced Diabetic Rats
Diabetes, September 1, 2001; 50(9): 2061 - 2068.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Lavoie, C. J. Band, M. Kong, J. J. M. Bergeron, and B. I. Posner
Regulation of Glycogen Synthase in Rat Hepatocytes. EVIDENCE FOR MULTIPLE SIGNALING PATHWAYS
J. Biol. Chem., October 1, 1999; 274(40): 28279 - 28285.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Cadène, F. Grigorescu, J.-J. Serrano, and G. Cros
Characterization of Vanadyl Sulfate Effect on Vascular Contraction: Roles of Calcium and Tyrosine Phosphorylation
J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 491 - 498.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
C. J. Band and B. I. Posner
Phosphatidylinositol 3'-Kinase and p70s6k Are Required for Insulin but Not Bisperoxovanadium 1,10-Phenanthroline (bpV(phen)) Inhibition of Insulin-like Growth Factor Binding Protein Gene Expression. EVIDENCE FOR MEK-INDEPENDENT ACTIVATION OF MITOGEN-ACTIVATED PROTEIN KINASE BY bpV(phen)
J. Biol. Chem., January 3, 1997; 272(1): 138 - 145.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1995 by the American Diabetes Association.